Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group.

By A. Bedikian, M. Millward, H. Pehamberger, R. Conry, M. Gore, U. Trefzer, A. Pavlick, R. Deconti, E. Hersh, P. Hersey and 2 more. Journal of Clinical Oncology, 2006

615 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/64eaa52fc7486154a11d125fde4c15e46862810c

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Bcl-2 family proteins and cancer (2008, background): “…phosphorothioate antisense oligonucleotide targeting Bcl-2 mRNA (oblimersen sodium), which has shown promising activity for chronic lymphocytic leukemia and malignant melanoma in randomized phase III trials (Reed et al., 1990; Klasa et al., 2002; Bedikian et al., 2006; O’Brien et al., 2007).”
The BCL-2 Family Reunion (2010, background): “One example is Genasense, a phosphorothioate oligodeoxynucleotide bcl-2 antisense, which has been shown to sensitize CLL patients to chemotherapy (Kang and Reynolds, 2009) and phase III trials suggest that Genasense may have efficiency in advanced melanoma with combination therapies (Bedikian et al.”
Melanoma biology and new targeted therapy (2007, background): “( Table 2 ) and a Phase III study has shown some benefit in progression-free survival when used in combination with dacarbazin”
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation (2011, neutral): “Arthralgia Grade 2 60 (18) 1 (<1) Grade 3 11 (3) 2 (<1) Rash Grade 2 33 (10) 0 Grade 3 28 (8) 0 Fatigue Grade 2 38 (11) 33 (12) Grade 3 6 (2) 5 (2) Cutaneous squamous-cell carcinoma‡ Grade 3 40 (12) 1 (<1) Keratoacanthoma§ Grade 2 7 (2) 0 Grade 3 20 (6) 0 Nausea Grade 2 25 (7) 32 (11) Grade 3 4 (1) ”